Table 2

Treatment outcomes

Patient# Cycles pembro# Cycles pomirAEΔCD4+*
T cells/μL
ΔCD8+
T cells/μL
Best responseNext therapy receivedMonths from pembro initiation to last follow-upLong-term outcome
113+116+311PRAllogeneic HSCT13Death
27G2 hypothyroidism+132+754SDTrimetinib11Death
36G2 hypothyroidism−63−152SDLenalidomide +bortezomib15SD
415−43−37PRR-ICE followed by allogeneic HSCT33CR
56+52+43PRRIL15Death
6712G3 Guillain-Barre−65−74SDHD-MTX-Ara-C-Thiotepa24SD
72219G3 hepatitis+70+517CRContinued on pembro+pom21CR
83−305−1458PD3Death
941PD4Death
1077+94+473PRDaratumumab+pom9PR
  • *The change in CD4+ and CD8+ T cells is measured from baseline to the end of treatment.

  • Ara-C, cytarabine; CR, complete response; G, grade; HD-MTX, high-dose methotrexate; HSCT, hematopoietic stem cell transplant; irAE, immune-related adverse event; PD, progressive disease; pembro, pembrolizumab; pom, pomalidomide; PR, partial response; R-ICE, rituximab, ifosfamide, carboplatin, etoposide; RIL, rituximab, ibrutinib, lenalidomide; SD, stable disease.